Insights & Publications
© 2018 Debevoise & Plimpton LLP
Private Equity Guide to Life Sciences Investing Under the Trump Administration: Food and Drug Administration (FDA) Developments
15 March 2018
View Debevoise In Depth
Under the leadership of Commissioner Scott Gottlieb, M.D., FDA has launched sweeping initiatives intended to accelerate drug and device approvals and clearances, encourage new technologies, and lower regulatory burdens to foster innovation and spur greater competition.
While collectively these are positive developments for the life sciences industry, private equity investors should keep a close watch on the regulatory landscape, particularly since the regulatory changes underway can affect different market players in different ways.
Areas under increased regulatory scrutiny, such as opioids and compounded drugs, may still represent investment opportunities for PE firms that can closely read the lay of the land and move with agility.
Mergers & Acquisitions
Consumer & Retail
Andrew L. Bab
Jennifer L. Chu
Paul D. Rubin
View More Authors
Debevoise Advises 4Refuel and Its Equityholders in the Sale of 4Refuel to Finning International
European Funds Comment: Reporting Emissions in the UK: Further Disclosures Coming
Medical Device Cybersecurity Report Advancing Coordinated Vulnerability Disclosure
Debevoise Advises Tribune Media in Its $6.4 Billion Sale to Nexstar Media Group
UK Modern Slavery Act Transparency Statement
Debevoise Women's Review